CU24441B1 - Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas - Google Patents

Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas

Info

Publication number
CU24441B1
CU24441B1 CU2016000131A CU20160131A CU24441B1 CU 24441 B1 CU24441 B1 CU 24441B1 CU 2016000131 A CU2016000131 A CU 2016000131A CU 20160131 A CU20160131 A CU 20160131A CU 24441 B1 CU24441 B1 CU 24441B1
Authority
CU
Cuba
Prior art keywords
bacterial infections
organic
treatment
compounds
monobactam compounds
Prior art date
Application number
CU2016000131A
Other languages
English (en)
Other versions
CU20160131A7 (es
Inventor
Virender Sigh Aulakh
Anthony Casarez
Xiaodong Lin
Mika Lindvall
Glenn Mcenroe
Heinz Ernst Moser
Folkert Reck
Robert Lowell Simmons
Meiliana Tjandra
Aregahegn Yifru
Qingming Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20160131A7 publication Critical patent/CU20160131A7/es
Publication of CU24441B1 publication Critical patent/CU24441B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

<p>Esta invención se refiere en general a compuestos antibacterianos de Ia Formula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>como se describe adicionalmente en este documento, y las sales trifluoroacetato y formato de los mismos. Los compuestos de la presente invención son activos para tratar infecciones bacterianas tales como las causadas por bacterias Gram-negativas.</p>
CU2016000131A 2014-03-24 2015-03-23 Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas CU24441B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US201462088304P 2014-12-05 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
CU20160131A7 CU20160131A7 (es) 2017-02-02
CU24441B1 true CU24441B1 (es) 2019-09-04

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000131A CU24441B1 (es) 2014-03-24 2015-03-23 Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas

Country Status (36)

Country Link
US (4) US9174978B2 (es)
EP (2) EP3122745B1 (es)
JP (1) JP6153674B2 (es)
KR (1) KR101733441B1 (es)
CN (1) CN106164072B (es)
AP (1) AP2016009374A0 (es)
AU (1) AU2015236369B2 (es)
BR (1) BR112016020333B1 (es)
CA (1) CA2939254C (es)
CL (1) CL2016002285A1 (es)
CU (1) CU24441B1 (es)
CY (1) CY1121701T1 (es)
DK (2) DK3511328T3 (es)
EA (1) EA030850B1 (es)
EC (1) ECSP16073620A (es)
ES (2) ES2719136T3 (es)
GT (1) GT201600183A (es)
HR (1) HRP20190501T1 (es)
HU (1) HUE042134T2 (es)
IL (1) IL247259B (es)
LT (1) LT3122745T (es)
MA (1) MA39777B1 (es)
MX (1) MX2016011822A (es)
MY (1) MY179292A (es)
PE (1) PE20161371A1 (es)
PH (1) PH12016501577A1 (es)
PL (1) PL3122745T3 (es)
PT (1) PT3122745T (es)
RS (1) RS58509B1 (es)
SG (1) SG11201606711UA (es)
SI (1) SI3122745T1 (es)
SV (1) SV2016005274A (es)
TW (1) TWI714525B (es)
UA (1) UA121383C2 (es)
WO (1) WO2015148379A1 (es)
ZA (1) ZA201605565B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092620A1 (ru) * 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
BR112018010962A8 (pt) * 2015-12-15 2023-04-11 Merck Sharp & Dohme Composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto
BR112018067930B1 (pt) 2016-03-07 2024-02-15 Merck Sharp & Dohme Llc Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto
JP7306997B2 (ja) 2017-03-20 2023-07-11 ザ・ブロード・インスティテュート・インコーポレイテッド 寄生虫性疾患の処置のための化合物および方法
JP7235718B2 (ja) * 2017-08-02 2023-03-08 ノバルティス アーゲー モノバクタム系抗生物質およびその中間体を製造するための化学的方法
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
JP6991345B2 (ja) * 2017-10-02 2022-01-12 アリクサ ファーマシューティカルズ、インコーポレイテッド アズトレオナム誘導体およびその使用
PE20201256A1 (es) 2017-10-02 2020-11-16 Merck Sharp & Dohme Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
US20200360349A1 (en) * 2017-11-10 2020-11-19 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
CN111511737B (zh) 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US20220002288A1 (en) 2018-11-13 2022-01-06 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
KR20220084398A (ko) * 2019-11-22 2022-06-21 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
WO2021121387A1 (zh) 2019-12-19 2021-06-24 南京明德新药研发有限公司 化合物在制药中的应用
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
EP4165039A4 (en) * 2020-07-16 2023-06-21 Ningxia Academy of Agriculture and Forestry Sciences MONOBACTAM COMPOUNDS, THEIR PRODUCTION AND USE AS ANTIBACTERIAL AGENTS
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
US11932637B2 (en) 2021-11-18 2024-03-19 Merck Sharp & Dohme Llc Chromane amidine monobactam compounds for the treatment of bacterial infections
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb &amp; Sons, Inc. Beta-lactam antibiotics
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) * 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd １−スルホ−２−アゼチジノン誘導体およびその製造法
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
SU1195908A3 (ru) 1982-05-31 1985-11-30 Баниу Фармасьютикал Ко.,Лтд.(Фирма) Способ получени производных 2-оксо-1-азетидинсульфокислоты или их солей с щелочными металлами
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
CN105315373B (zh) 2005-05-09 2018-11-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
SI2231667T1 (sl) 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027828A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
HUE031802T2 (en) 2008-10-31 2017-08-28 Shionogi & Co Catechol Cephalosporin
SG196798A1 (en) 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
RU2646139C1 (ru) 2009-09-03 2018-03-01 Мерк Шарп И Доум Корп. Анти-gitr-антитела
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN105693861A (zh) 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
WO2012073138A1 (en) * 2010-11-29 2012-06-07 Pfizer Inc. Monobactams
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2961751B1 (en) 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Also Published As

Publication number Publication date
LT3122745T (lt) 2019-04-10
CU20160131A7 (es) 2017-02-02
UA121383C2 (uk) 2020-05-25
HRP20190501T1 (hr) 2019-05-03
JP6153674B2 (ja) 2017-06-28
ES2719136T3 (es) 2019-07-08
BR112016020333A2 (pt) 2017-10-24
HUE042134T2 (hu) 2019-06-28
BR112016020333B1 (pt) 2022-08-09
US20190231752A1 (en) 2019-08-01
CA2939254C (en) 2023-02-14
CL2016002285A1 (es) 2016-12-30
CY1121701T1 (el) 2020-07-31
NZ723114A (en) 2020-12-18
MA39777B1 (fr) 2019-03-29
SG11201606711UA (en) 2016-10-28
MY179292A (en) 2020-11-03
EP3122745A1 (en) 2017-02-01
RS58509B1 (sr) 2019-04-30
SI3122745T1 (sl) 2019-05-31
CA2939254A1 (en) 2015-10-01
EA030850B1 (ru) 2018-10-31
PT3122745T (pt) 2019-04-30
DK3122745T3 (en) 2019-04-08
SV2016005274A (es) 2018-06-12
TW201540712A (zh) 2015-11-01
KR101733441B1 (ko) 2017-05-10
EP3511328B1 (en) 2021-03-03
ECSP16073620A (es) 2018-12-31
AU2015236369B2 (en) 2017-02-16
AU2015236369A1 (en) 2016-09-01
CN106164072A (zh) 2016-11-23
MA39777A (fr) 2017-02-01
US20200276169A1 (en) 2020-09-03
US20160051523A1 (en) 2016-02-25
GT201600183A (es) 2018-12-18
EP3511328A1 (en) 2019-07-17
MX2016011822A (es) 2016-12-02
ES2862203T3 (es) 2021-10-07
IL247259B (en) 2020-02-27
DK3511328T3 (da) 2021-03-22
US10369138B2 (en) 2019-08-06
ZA201605565B (en) 2017-09-27
US20150266867A1 (en) 2015-09-24
TWI714525B (zh) 2021-01-01
IL247259A0 (en) 2016-09-29
EA201691766A1 (ru) 2016-12-30
JP2017510580A (ja) 2017-04-13
WO2015148379A1 (en) 2015-10-01
PE20161371A1 (es) 2016-12-21
PH12016501577A1 (en) 2016-10-03
AP2016009374A0 (en) 2016-08-31
EP3122745B1 (en) 2019-02-27
KR20160110541A (ko) 2016-09-21
CN106164072B (zh) 2019-10-01
US9174978B2 (en) 2015-11-03
PL3122745T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
CU24441B1 (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
CU24443B1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
ES2898695T8 (es) Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
ECSP14013273A (es) Compuestos antibacterianos y métodos para su uso
ECSP19016602A (es) Inhibidores de beta-lactamasa
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
UY34755A (es) Agentes para el control de la glycaspis brimblecombei
UY36043A (es) COMPUESTOS ORGÁNICOS DE MONOBACbTAM PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS
CR20160412A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
AR084421A1 (es) Betametasona como agente antibacteriano
ES1077006Y (es) Aparato para curar infecciones causadas por bacterias y microorganismos fotosensibles.